代谢相关脂肪性肝病的中西医诊疗思考与对策  

Considerations and countermeasures for the treatment of metabolic associated fatty liver disease in Chinese and Western medicine

作　　者：张国红 李晓东[2,3] 周亚娜[2,3] 徐曦 肖明中[2,3] ZHANG Guo-hong;LI Xiao-dong;ZHOU Ya-na;XIAO Ming-zhong(Xujiapeng Branch,Hubei Provincial Hospital of Traditional Chinese Medicine,Wuhan Hubei,430061,China)

机构地区：[1]湖北省中医院徐家棚分院,湖北武汉430061 [2]湖北省中医院肝病研究所 [3]湖北省中医院中医肝肾研究及应用湖北省重点实验室

出　　处：《中西医结合肝病杂志》2021年第6期493-497,共5页Chinese Journal of Integrated Traditional and Western Medicine on Liver Diseases

基　　金：湖北省自然科学基金创新群体项目(No.2020CFA023);全国名老中医药专家盛国光传承工作室建设项目(No.国中医药人教函2018-134号);国家中医药管理局临床研究基地建设项目(No.JDZX2015168)。

摘　　要：2020年5月,国际专家小组发布了《代谢相关脂肪性肝病的诊断和管理共识》,提出采用MAFLD取代现有命名“非酒精性脂肪性肝病(NAFLD)”的立场声明,进一步明确了MAFLD的临床诊疗指导意见。本文就MAFLD的广泛疾病谱、治疗应答不佳、易感基因与表观遗传因素、医患对疾病认识不足等现状以及MAFLD的西医诊断评估进行阐述,并通过学习仝小林团队创建的脾瘅理论,从代谢综合征(膏浊病)的整体角度思考中医肝癖(MAFLD)的病因病机,中医诊治MAFLD的优势等方面,探讨MAFLD(肝癖病)的中西医诊疗对策。In May 2020,the international expert panel released the"Consensus on the Diagnosis and Management of Metabolic Associated Fatty Liver Disease(MAFLD)",proposing the use of the term"MAFLD"to replace the existing name"Non-Alcoholic Fatty Liver Disease(NAFLD)".The position statement further clarifies the clinical diagnosis and management guidelines for MAFLD.In this paper,we discuss the broad disease spectrum of MAFLD,the poor response to treatment,susceptibility genes and epigenetic factors,and the insufficient understanding of the disease by doctors and patients,as well as the Western diagnostic evaluation of MAFLD.We will discuss the Chinese and Western medicine treatment and countermeasures for MAFLD.

关 键 词：代谢相关脂肪性肝病 肝癖病 脾瘅 膏浊病 中西医诊疗对策 

分 类 号：R575[医药卫生—消化系统]